Medical devices company Tissue Regenix (TRX) - the owner of patented 'dCELL' technology - has retained the confidence of its investors since the shares jumped over 150 per cent during the nine months to May. That reflects the company's successful launch of its Dermapure product, which is aimed at treating chronic wounds, on time in the US. This leaves the company well on the way towards targeting the skin-substitutes market, estimated to be worth $1.4bn (£867m).
While US sales of Dermapure begin building, the company is developing more treatments from its dCELL platform. The patented technology helps remove DNA from animal and human tissue before it is re-inserted into patients to naturally regenerate diseased or wounded parts of the body.